initial public offerings (IPOs) trading on American exchanges

Friday, April 13, 2018

Spero Therapeutics (SPRO) began trading on the Nasdaq on Thur 2 Nov 17

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. 
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 41
  • Founded in 2013 
  • Headquartered in Cambridge, Massachusetts.

Spero Therapeutics (NASDAQ:SPRO) priced its initial public offering to the low end of its range, at $14.
It had marketed at $14-$16/share. 
It offered 5.5M common shares at that price, for a raise of $77M.
Shares opened at $13.25, ~5% lower than the offer price of $14.

No comments:

Post a Comment